FierceBiotech Radio with NEA's Carol Gallagher

New Enterprise Associates Partner Carol Gallagher

New Enterprise Associates Partner Carol Gallagher joins FierceBiotech Radio to talk about her journey from Big Pharma to small biotech and eventually to venture capital, along the way shedding light on just what VCs do all day.

Download the episode on iTunes or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected] And if you missed last week's interview with Michael Gilman, CEO of the Atlas Venture-seeded Padlock Therapeutics, you can find it here.

Suggested Articles

Journey Colab launches with $3 million from Apollo Projects to develop a pipeline of psychedelic compounds through a new development model.

Forma's lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with relapsed or refractory acute myeloid leukemia.

A type of white blood cell known as a granulocyte secretes growth factors that help axons of the central nervous system regenerate, researchers found.